Olivier Taelman
Vermögen: 37 634 $ am 31.05.2026
Vermögen: 37 634 $ am 31.05.2026
Olivier Taelman currently works at Nyxoah SA, as Chief Executive Officer & Executive Director from 2020.
Mr. Taelman also formerly worked at Nevro Corp., as Business Director-Neuromodulation from 2013 to 2015 and Autonomic Technologies, Inc., as Vice President-Europe from 2015 to 2019.
Mr. Taelman received his undergraduate degree from Hasselt University and Masters Business Admin degree from The Wharton School of the University of Pennsylvania.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NYXOAH SA 0.01% | 01.03.2026 | 12’500 ( 0.01% ) | 37 634 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| NYXOAH SA | Vorstandsvorsitzender | 01.11.2019 |
| Unternehmen | Position | Ende |
|---|---|---|
Autonomic Technologies, Inc.
Autonomic Technologies, Inc. Medical SpecialtiesHealth Technology Manufactures medical devices for the treatment of severe headache autonomic disorder | Corporate Officer/Principal | 01.11.2019 |
| NEVRO CORP. | Corporate Officer/Principal | 01.12.2015 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
Autonomic Technologies, Inc.
Autonomic Technologies, Inc. Medical SpecialtiesHealth Technology Manufactures medical devices for the treatment of severe headache autonomic disorder | Health Technology |
Hasselt University
Hasselt University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nevro Corp.
Nevro Corp. Medical SpecialtiesHealth Technology Operates as a medical device company | Health Technology |
The Wharton School of the University of Pennsylvania
The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nyxoah SA
Nyxoah SA Medical SpecialtiesHealth Technology Manufactures neurostimulation devices for treating obstructive sleep apnea | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen